Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease

References

• Anon. Standards of medical care in diabetes – 2007. Diabetes Care 2007;30( Suppl 1):S4–S411. Anon. Standards of medical care in diabetes – 2007. Diabetes Care 2007;30(Suppl 1):S4–S41
   PubMedGoogle Scholar
• Anon. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–532. Anon. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–173. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103–17
   PubMed Web of Science ®Google Scholar
• Buse JB. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:S21–S334. Buse JB. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:S21–S33
   PubMed Web of Science ®Google Scholar
• Anon. Major international diabetes study does not confirm increased risk of death reported by US trial. Available at: http://www.advance-trial.com/static/upload/PDF/Media_release_Feb08.pdf [last accessed March 10, 2008]5. Anon. Major international diabetes study does not confirm increased risk of death reported by US trial. Available at: http://www.advance-trial.com/static/upload/PDF/Media_release_Feb08.pdf [last accessed March 10, 2008]
   Google Scholar
• Abraira C, Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003;17:314–226. Abraira C, Duckworth W, McCarren M, et al. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications 2003;17:314–22
   PubMed Web of Science ®Google Scholar
• Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004;291:335–427. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. J Am Med Assoc 2004;291:335–42
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 1999;281:2005–128. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). J Am Med Assoc 1999;281:2005–12
   PubMed Web of Science ®Google Scholar
• Kulkarni K. Diets do not fail: the success of medical nutrition therapy in patients with diabetes. Endocr Pract 2006;12 Suppl 1:121–39. Kulkarni K. Diets do not fail: the success of medical nutrition therapy in patients with diabetes. Endocr Pract 2006;12 Suppl 1:121–3
   PubMedGoogle Scholar
• PRECOSE (acarbose tablets) prescribing information. Available at: http://www.univgraph.com/Bayer/inserts/Precose.pdf [last accessed July 26, 2007]10. PRECOSE (acarbose tablets) prescribing information. Available at: http://www.univgraph.com/Bayer/inserts/Precose.pdf [last accessed July 26, 2007]
   Google Scholar
• GLYSET(miglitol tablets) prescribing information. Available at: http://www.pfizer.com/files/products/uspi_glyset.pdf [last accessed July 26, 2007]11. GLYSET(miglitol tablets) prescribing information. Available at: http://www.pfizer.com/files/products/uspi_glyset.pdf [last accessed July 26, 2007]
   Google Scholar
• GLUCOPHAGE XR (metformin hydrochloride extended-release tablets) prescribing information. Available at: [http://packageinserts.bms.com/pi/pi_glucophage_xr.pdf [last accessed November 1, 2006]12. GLUCOPHAGE XR (metformin hydrochloride extended-release tablets) prescribing information. Available at: [http://packageinserts.bms.com/pi/pi_glucophage_xr.pdf [last accessed November 1, 2006]
   Google Scholar
• JANUVIA (sitagliptin tablets) prescribing information. Available at: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf [last accessed July 26, 2007]13. JANUVIA (sitagliptin tablets) prescribing information. Available at: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf [last accessed July 26, 2007]
   Google Scholar
• STARLIX (nateglinide tablets) prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/Starlix.pdf [last accessed July 26, 2007]14. STARLIX (nateglinide tablets) prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/Starlix.pdf [last accessed July 26, 2007]
   Google Scholar
• PRANDIN (repaglinide tablets) prescribing information. Available at: http://www.prandin.com/docs/prandin_insert.pdf [last accessed July 26, 2007]15. PRANDIN (repaglinide tablets) prescribing information. Available at: http://www.prandin.com/docs/prandin_insert.pdf [last accessed July 26, 2007]
   Google Scholar
• MICRONASE (glyburide) prescribing information. Available at: http://www.pfizer.com/files/products/uspi_micronase.pdf [last accessed November 1, 2006]16. MICRONASE (glyburide) prescribing information. Available at: http://www.pfizer.com/files/products/uspi_micronase.pdf [last accessed November 1, 2006]
   Google Scholar
• AMARYL (glimepiride tablets) prescribing information. Available at: http://products.sanofi-aventis.us/amaryl/amaryl.pdf [last accessed July 26, 2007]17. AMARYL (glimepiride tablets) prescribing information. Available at: http://products.sanofi-aventis.us/amaryl/amaryl.pdf [last accessed July 26, 2007]
   Google Scholar
• GLUCOTROL XL (glipizide) extended release tablets prescribing information. Available at: http://www.pfizer.com/files/products/uspi_glucotrol_xl.pdf [last accessed December 9, 2007]18. GLUCOTROL XL (glipizide) extended release tablets prescribing information. Available at: http://www.pfizer.com/files/products/uspi_glucotrol_xl.pdf [last accessed December 9, 2007]
   Google Scholar
• AVANDIA (rosiglitazone maleate tablets) prescribing information. Available at: http://us.gsk.com/products/assets/us_avandia.pdf [last accessed July 26, 2007]19. AVANDIA (rosiglitazone maleate tablets) prescribing information. Available at: http://us.gsk.com/products/assets/us_avandia.pdf [last accessed July 26, 2007]
   Google Scholar
• ACTOS (pioglitazone hydrochloride tablets) prescribing information. Available at: http://www.actos.com/actos/prescribinginfo.aspx [last accessed July 26, 2007]20. ACTOS (pioglitazone hydrochloride tablets) prescribing information. Available at: http://www.actos.com/actos/prescribinginfo.aspx [last accessed July 26, 2007]
   Google Scholar
• Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097–10421. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097–104
   PubMed Web of Science ®Google Scholar
• IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation; 200522. IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation; 2005
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). |Lancet| 1998;352:854–6523. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). |Lancet| 1998;352:854–65
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963–7224. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963–72
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 2007;356:2457–7125. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New Engl J Med 2007;356:2457–71
   PubMed Web of Science ®Google Scholar
• Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19 Suppl:789–83026. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19 Suppl:789–830
   PubMedGoogle Scholar
• JANUMET (sitagliptin-metformin combination tablets) prescribing information. Available at: http://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_pi.pdf [last accessed July 26, 2007]27. JANUMET (sitagliptin-metformin combination tablets) prescribing information. Available at: http://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_pi.pdf [last accessed July 26, 2007]
   Google Scholar
• Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376–8628. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008;10:376–86
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Hissa M, Blauwet MB, et al. Saxagliptin added to metformin improves glycemia control in patients with type 2 diabetes, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 200729. DeFronzo RA, Hissa M, Blauwet MB, et al. Saxagliptin added to metformin improves glycemia control in patients with type 2 diabetes, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 2007
   Google Scholar
• Takeda submits new drug application for alogliptin (SYR-322) in the US. Available at: http://www.takeda.com/press/article_28864.html [last accessed March 15, 2008]30. Takeda submits new drug application for alogliptin (SYR-322) in the US. Available at: http://www.takeda.com/press/article_28864.html [last accessed March 15, 2008]
   Google Scholar
• Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632–731. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632–7
   PubMed Web of Science ®Google Scholar
• Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564–7132. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564–71
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638–4333. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638–43
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556–6834. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556–68
   PubMed Web of Science ®Google Scholar
• Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423–835. Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 2006;38:423–8
   PubMed Web of Science ®Google Scholar
• Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218–2336. Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218–23
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132–837. Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007;76:132–8
   PubMed Web of Science ®Google Scholar
• Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabetic Med 2007;24:955–6138. Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabetic Med 2007;24:955–61
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217–2339. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217–23
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175–8540. Rosenstock J, Baron MA, Camisasca RP, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:175–85
   PubMed Web of Science ®Google Scholar
• Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890–541. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890–5
   PubMed Web of Science ®Google Scholar
• Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874–8042. Ahren B, Gomis R, Standl E, et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874–80
   PubMed Web of Science ®Google Scholar
• Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936–4043. Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936–40
   PubMed Web of Science ®Google Scholar
• Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166–7444. Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab 2007;9:166–74
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Cravatt BF. Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 2005;115:1130–345. Lichtman AH, Cravatt BF. Food for thought: endocannabinoid modulation of lipogenesis. J Clin Invest 2005;115:1130–3
   PubMed Web of Science ®Google Scholar
• Finer N, Pagotto U. The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. Br J Diabetes Vasc Dis 2005;5:121–446. Finer N, Pagotto U. The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. Br J Diabetes Vasc Dis 2005;5:121–4
   Google Scholar
• Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl J Med 2005;353:2121–3447. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl J Med 2005;353:2121–34
   PubMed Web of Science ®Google Scholar
• Iranmanesh A, Rosenstock J. Late-breaking trial: SERENADE, International Diabetes Federation 19th World Diabetes Congress, Cape Town, South Africa, December 3–7, 200648. Iranmanesh A, Rosenstock J. Late-breaking trial: SERENADE, International Diabetes Federation 19th World Diabetes Congress, Cape Town, South Africa, December 3–7, 2006
   Google Scholar
• New data shows Acomplia (rimonabant) benefited patients with type 2 diabetes by improving blood sugar control, reducing weight and acting on other cardiometabolic risk factors. Available at: http://en.sanofi-aventis.com/press/ppc_14733.asp [last accessed May 15, 2008]49. New data shows Acomplia (rimonabant) benefited patients with type 2 diabetes by improving blood sugar control, reducing weight and acting on other cardiometabolic risk factors. Available at: http://en.sanofi-aventis.com/press/ppc_14733.asp [last accessed May 15, 2008]
   Google Scholar
• Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660–7250. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660–72
   PubMed Web of Science ®Google Scholar
• Bermudez-Siva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006;531:282–451. Bermudez-Siva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006;531:282–4
   PubMed Web of Science ®Google Scholar
• Cleland SJ, Sattar N. Does rimonabant pull its weight for type 2 diabetes? Lancet 2006;368:1632–452. Cleland SJ, Sattar N. Does rimonabant pull its weight for type 2 diabetes? Lancet 2006;368:1632–4
   Google Scholar
• Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706–1353. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706–13
   PubMed Web of Science ®Google Scholar
• Insull Jr W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006;99:257–7354. Insull Jr W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006;99:257–73
   PubMed Web of Science ®Google Scholar
• De Fabiani E, Mitro N, Gilardi F, et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003;278:39124–3255. De Fabiani E, Mitro N, Gilardi F, et al. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 2003;278:39124–32
   PubMed Web of Science ®Google Scholar
• Suzuki T, Oba K, Futami S, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006;73:277–8456. Suzuki T, Oba K, Futami S, et al. Blood glucose-lowering activity of colestimide in patients with type 2 diabetes and hypercholesterolemia: a case-control study comparing colestimide with acarbose. J Nippon Med Sch 2006;73:277–84
   PubMedGoogle Scholar
• Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004;279:23158–6557. Yamagata K, Daitoku H, Shimamoto Y, et al. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 2004;279:23158–65
   PubMed Web of Science ®Google Scholar
• Bandisode MS, Boshell BR. Hypocholesterolemic activity of colestipol in diabetes. Curr Ther Res Clin Exp 1975;18:276–8458. Bandisode MS, Boshell BR. Hypocholesterolemic activity of colestipol in diabetes. Curr Ther Res Clin Exp 1975;18:276–84
   PubMed Web of Science ®Google Scholar
• Duntsch G. [Colestipol by hypercholesteremia in diabetics]. Fortschr Med 1977;95:1492–659. Duntsch G. [Colestipol by hypercholesteremia in diabetics]. Fortschr Med 1977;95:1492–6
   PubMedGoogle Scholar
• Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416–2260. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 1994;121:416–22
   PubMed Web of Science ®Google Scholar
• Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL-cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980–761. Tonolo G, Melis MG, Formato M, et al. Additive effects of simvastatin beyond its effects on LDL-cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000;30:980–7
   PubMed Web of Science ®Google Scholar
• Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007;54:53–862. Yamakawa T, Takano T, Utsunomiya H, et al. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. Endocr J 2007;54:53–8
   PubMed Web of Science ®Google Scholar
• Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74–8363. Zieve FJ, Kalin MF, Schwartz SL, et al. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74–83
   PubMed Web of Science ®Google Scholar
• Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779–9064. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779–90
   PubMed Web of Science ®Google Scholar
• Braunlin W, Zhorov E, Smisek D. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polymer Preprints 2000;41:708–965. Braunlin W, Zhorov E, Smisek D. In vitro comparison of bile acid binding to colesevelam HCl and other bile acid sequestrants. Polymer Preprints 2000;41:708–9
   Google Scholar
• Bailey WL, Jones MR, Abby SL. Colesevelam HCl for the management of type 2 diabetes mellitus?: rationale for a clinical trial program, American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 26–29, 200666. Bailey WL, Jones MR, Abby SL. Colesevelam HCl for the management of type 2 diabetes mellitus?: rationale for a clinical trial program, American College of Clinical Pharmacy Annual Meeting, St. Louis, MO, October 26–29, 2006
   Google Scholar
• Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin 2007;23:1673–8467. Bays HE, Cohen DE. Rationale and design of a prospective clinical trial program to evaluate the glucose-lowering effects of colesevelam HCl in patients with type 2 diabetes mellitus. Curr Med Res Opin 2007;23:1673–84
   PubMed Web of Science ®Google Scholar
• WELCHOL (colesevelam HCl tablets) prescribing information. Available at: http://www.welchol.com/pdf/Welchol_PI.pdf [last accessed May 15, 2008]68. WELCHOL (colesevelam HCl tablets) prescribing information. Available at: http://www.welchol.com/pdf/Welchol_PI.pdf [last accessed May 15, 2008]
   Google Scholar
• Parker JC, Irwin N, Lavery KS, et al. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9–39)amide in obese diabetic (ob/ob) mice. Biol Chem 2007;388:221–669. Parker JC, Irwin N, Lavery KS, et al. Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9–39)amide in obese diabetic (ob/ob) mice. Biol Chem 2007;388:221–6
   PubMed Web of Science ®Google Scholar
• Irwin N, McClean PL, O'Harte F P, et al. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro(3))GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 2007;50:1532–4070. Irwin N, McClean PL, O'Harte F P, et al. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro(3))GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 2007;50:1532–40
   PubMed Web of Science ®Google Scholar
• Shah OJ, Kimball SR, Jefferson LS. The Src-family tyrosine kinase inhibitor PP1 interferes with the activation of ribosomal protein S6 kinases. Biochem J 2002;366:57–6271. Shah OJ, Kimball SR, Jefferson LS. The Src-family tyrosine kinase inhibitor PP1 interferes with the activation of ribosomal protein S6 kinases. Biochem J 2002;366:57–62
   PubMed Web of Science ®Google Scholar
• Tremblay F, Krebs M, Dombrowski L, et al. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 2005;54:2674–8472. Tremblay F, Krebs M, Dombrowski L, et al. Overactivation of S6 kinase 1 as a cause of human insulin resistance during increased amino acid availability. Diabetes 2005;54:2674–84
   PubMed Web of Science ®Google Scholar
• Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88:285–9173. Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88:285–91
   PubMed Web of Science ®Google Scholar
• Schwartz S, Rendell M, Ahmann A, et al. Metabolic effects of 14-day treatment with DIO-902: results of a randomized, placebo-controlled trial in patients with type 2 diabetes, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 200774. Schwartz S, Rendell M, Ahmann A, et al. Metabolic effects of 14-day treatment with DIO-902: results of a randomized, placebo-controlled trial in patients with type 2 diabetes, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 2007
   Google Scholar
• Leighton B, Atkinson A, Coghlan MP. Small molecule glucokinase activators as novel anti-diabetic agents. Biochem Soc Trans 2005;33:371–475. Leighton B, Atkinson A, Coghlan MP. Small molecule glucokinase activators as novel anti-diabetic agents. Biochem Soc Trans 2005;33:371–4
   PubMed Web of Science ®Google Scholar
• Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003;12:223–3376. Zhang ZY, Lee SY. PTP1B inhibitors as potential therapeutics in the treatment of type 2 diabetes and obesity. Expert Opin Investig Drugs 2003;12:223–33
   PubMed Web of Science ®Google Scholar
• Hussey EK, Clark RV, Amin DM, et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor or renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 200777. Hussey EK, Clark RV, Amin DM, et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of sergliflozin, a novel inhibitor or renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 2007
   Google Scholar
• Hussey EK, Dobbins RL, Stolz RR, et al. A double-blind randomized repeat dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy, overweight and obese subjects, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 200778. Hussey EK, Dobbins RL, Stolz RR, et al. A double-blind randomized repeat dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of three times daily dosing of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy, overweight and obese subjects, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 2007
   Google Scholar
• van Poelje PD, Potter SC, Chandramouli VC, et al. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. Diabetes 2006;55:1747–5479. van Poelje PD, Potter SC, Chandramouli VC, et al. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats. Diabetes 2006;55:1747–54
   PubMed Web of Science ®Google Scholar
• Okuno A, Takahashi K, Tanaka J, et al. CS-917, a fructose 1,6-bisphosphate inhibitor, suppresses gluconeogenesis in human hepatocytes, whereas metformin stimulates glycolysis in Caco-2 cells, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 200780. Okuno A, Takahashi K, Tanaka J, et al. CS-917, a fructose 1,6-bisphosphate inhibitor, suppresses gluconeogenesis in human hepatocytes, whereas metformin stimulates glycolysis in Caco-2 cells, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 2007
   Google Scholar
• Van Poelje PD, Potter SC, Haughey MP, et al. MB06322 (CS-917), but not metformin, lowers blood glucose by inhibiting gluconeogenesis in Zucker diabetic fatty rats, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 200781. Van Poelje PD, Potter SC, Haughey MP, et al. MB06322 (CS-917), but not metformin, lowers blood glucose by inhibiting gluconeogenesis in Zucker diabetic fatty rats, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 2007
   Google Scholar
• Walker JR, Triscari J, Freudenth S, et al. Pharmacokinetics and pharmacodynamics of single-dose CS-917, a novel prodrug of a fructose 1,6-bisphosphate inhibitor, in patients with type 2 diabetes, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 200782. Walker JR, Triscari J, Freudenth S, et al. Pharmacokinetics and pharmacodynamics of single-dose CS-917, a novel prodrug of a fructose 1,6-bisphosphate inhibitor, in patients with type 2 diabetes, 67th Annual American Diabetes Association Scientific Sessions, Chicago, IL, June 22–26, 2007
   Google Scholar